105 studies found for:    MPL
Show Display Options
Rank Status Study
1 Active, not recruiting A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL
Condition: Allergic Rhinitis
Interventions: Biological: Grass MATA MPL 10200;   Biological: Grass MATA MPL 18200;   Biological: Placebo
2 Completed Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen
Condition: Type I Hypersensitivity
Intervention: Biological: OralvacB2MPL
3 Active, not recruiting A Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using Mobile EECs
Condition: Seasonal Allergic Rhinitis
Interventions: Biological: Placebo (0.5ml);   Biological: Placebo (1.0ml);   Biological: Grass MATA MPL (0.5ml) 5100SU;   Biological: Grass MATA MPL (1.0ml) 10200SU;   Biological: Grass MATA MPL (1.0ml) 18200SU;   Biological: Grass MATA (0.5ml) 5100SU
4 Completed Efficacy and Safety/Tolerability of Grass MATA MPL
Condition: Type I Hypersensitivity
Interventions: Biological: Grass MATA MPL;   Biological: Placebo
5 Completed Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine
Condition: Type I Hypersensitivity
Intervention: Biological: Tree MATA MPL
6 Completed Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents
Condition: Hepatitis B
Interventions: Biological: HBV-MPL vaccine Formulation A;   Biological: HBV-MPL vaccine Formulation B;   Biological: Engerix™-B
7 Completed Efficacy and Safety/Tolerability of Ragweed MATA MPL
Condition: Type I Hypersensitivity
Intervention: Biological: Ragweed MATA MPL
8 Completed Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen
Condition: Type I Hypersensitivity
Intervention: Biological: Tree MATA MPL
9 Completed Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing
Condition: Type I Hypersensitivity
Intervention: Biological: Ragweed MATA MPL
10 Completed Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y
Condition: Hepatitis B
Interventions: Biological: HBV-MPL vaccine;   Biological: Engerix™-B
11 Completed Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y
Condition: Hepatitis B
Interventions: Biological: HBV-MPL vaccine;   Biological: Engerix™-B
12 Completed LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine
Condition: Leishmaniasis
Interventions: Biological: MPL-SE;   Biological: LEISH-F3;   Biological: GLA-SE;   Drug: SE
13 Completed Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules
Condition: Hepatitis B
Interventions: Biological: Engerix™-B;   Biological: HBV-MPL vaccine
14 Completed
Has Results
A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis
Condition: Cutaneous Leishmaniasis
Interventions: Biological: LEISH-F2 + MPL-SE;   Drug: Sodium stibogluconate
15 Completed Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults
Condition: Hepatitis B
Interventions: Biological: HBV-MPL vaccine;   Biological: Engerix™-B
16 Completed Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).
Condition: Hepatitis B
Interventions: Biological: HBV-MPL vaccine 208129;   Biological: Engerix™-B
17 Completed Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients
Condition: Hepatitis B
Interventions: Biological: HBV-MPL vaccine 208129;   Biological: Engerix™-B
18 Completed Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine
Condition: Type I Hypersensitivity
Intervention: Biological: Grass MATAMPL
19 Active, not recruiting 577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy
Condition: Acute Central Serous Chorioretinopathy
Interventions: Device: 577-MPL;   Device: HD-PDT
20 Completed Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India
Conditions: Visceral Leishmaniasis;   Post-kala-azar Dermal Leishmaniasis
Intervention: Biological: Leish-111f + MPL-SE Adjuvant

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years